Literature DB >> 30956073

Safety and Efficacy of Radiofrequency Ablation for Nonfunctioning Benign Thyroid Nodules in Children and Adolescents in 14 Patients over a 10-Year Period.

Min Ji Hong1, Jin Yong Sung2, Jung Hwan Baek3, Mi Su Je4, Dong Whan Choi5, Hyunju Yoo6, Sae Jeong Yang7, Sang Yu Nam1, Eun Young Yoo1.   

Abstract

PURPOSE: To evaluate the efficacy and safety of radiofrequency (RF) ablation for nonfunctioning benign thyroid nodules in children and adolescents.
MATERIALS AND METHODS: Fourteen pediatric patients (10 female, 4 male; mean age 15.7 ± 2.3 years, range 12-19 years) with nonfunctioning benign thyroid nodules (mean longest diameter 3.7 ± 1.1 cm, range 2.0-5.6 cm) treated with the use of RF ablation from 2005 to 2015 were evaluated. The inclusion criteria for RF ablation therapy were (i) age <20 years, (ii) benign cytological confirmation by ≥2 separate fine-needle aspiration or core needle biopsies, (iii) pressure symptoms or cosmetic problems caused by thyroid nodules, (iv) absence of any suspicious feature as determined with the use of ultrasound (US), (v) normal serum levels of thyroid hormone and thyrotropin, and (vi) follow-up of >6 months. RF ablation was performed with the use of an RF generator and an 18-gauge internally cooled electrode. RF ablation was performed under local anesthesia without conscious sedation or general anesthesia. Changes in nodules on follow-up US, changes in symptomatic and cosmetic scores, and complications arising during or after RF ablation were evaluated.
RESULTS: Mean follow-up period was 36.9 ± 21.7 months (range 6-69 months). At last follow-up visits, mean longest nodule diameter and volume had decreased significantly (3.7 ± 1.1 cm vs 1.4 ± 0.9 cm and 14.6 ± 13.3 mL vs 1.7 ± 4.4 mL; P < 0.001). Both cosmetic and compressive symptoms significantly improved (3.8 ± 0.6 vs 1.4 ± 0.6 and 3.4 ± 1.0 vs 0.1 ± 0.4; P < 0.001). The mean number of ablation sessions was 2.1 ± 1.2 (range 1-5 sessions) and no major complication was encountered during or after RF ablation.
CONCLUSIONS: RF ablation might be a safe and effective treatment modality for nonfunctioning benign thyroid nodules in children and adolescents.
Copyright © 2018 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 30956073     DOI: 10.1016/j.jvir.2018.10.034

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  6 in total

1.  Long-Term Results of Thermal Ablation of Benign Thyroid Nodules: A Systematic Review and Meta-Analysis.

Authors:  Se Jin Cho; Jung Hwan Baek; Sae Rom Chung; Young Jun Choi; Jeong Hyun Lee
Journal:  Endocrinol Metab (Seoul)       Date:  2020-06-24

2.  Quality of Life in Papillary Thyroid Microcarcinoma Patients Undergoing Radiofrequency Ablation or Surgery: A Comparative Study.

Authors:  Yu Lan; Yukun Luo; Mingbo Zhang; Zhuang Jin; Jing Xiao; Lin Yan; Yaqiong Zhu
Journal:  Front Endocrinol (Lausanne)       Date:  2020-05-15       Impact factor: 5.555

3.  Radiofrequency Ablation for Cervical Metastatic Lymph Nodes in Children and Adolescents With Papillary Thyroid Carcinoma: A Preliminary Study.

Authors:  Lin Yan; Ying Zhang; Bo Jiang; Yukun Luo
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-18       Impact factor: 5.555

4.  Radiofrequency Ablation a Safe and Effective Treatment for Pediatric Benign Nodular Thyroid Goiter.

Authors:  An-Ni Lin; Wei-Che Lin; Kai-Lun Cheng; Sheng-Dean Luo; Pi-Ling Chiang; Wei-Chih Chen; Yueh-Sheng Chen; Cheng-Kang Wang; Na-Ning Kan; Yan-Ye Su
Journal:  Front Pediatr       Date:  2021-11-26       Impact factor: 3.418

5.  Long-Term Results of Ultrasound-Guided Radiofrequency Ablation of Benign Thyroid Nodules: State of the Art and Future Perspectives-A Systematic Review.

Authors:  Hervé Monpeyssen; Ahmad Alamri; Adrien Ben Hamou
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-26       Impact factor: 5.555

6.  Safety and Efficacy of Radiofrequency Ablation of Thyroid Nodules-Expanding Treatment Options in the United States.

Authors:  Iram Hussain; Fizza Zulfiqar; Xilong Li; Shahzad Ahmad; Jules Aljammal
Journal:  J Endocr Soc       Date:  2021-06-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.